<VariationArchive VariationID="640935" VariationName="NM_002693.3(POLG):c.3255dup (p.Ser1086fs)" VariationType="Duplication" Accession="VCV000640935" Version="6" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-02-28" DateCreated="2019-08-14" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="643599" VariationID="640935">
      <GeneList>
        <Gene Symbol="POLG" FullName="DNA polymerase gamma, catalytic subunit" GeneID="5428" HGNC_ID="HGNC:9179" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>15q26.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="89316320" stop="89334824" display_start="89316320" display_stop="89334824" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="89859535" stop="89878025" display_start="89859535" display_stop="89878025" Strand="-" />
          </Location>
          <OMIM>174763</OMIM>
        </Gene>
        <Gene Symbol="POLGARF" FullName="POLG alternative reading frame" GeneID="125316803" HGNC_ID="HGNC:56246" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>15q26.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="89316320" stop="89334824" display_start="89316320" display_stop="89334824" Strand="-" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_002693.3(POLG):c.3255dup (p.Ser1086fs)</Name>
      <CanonicalSPDI>NC_000015.10:89318948:GGG:GGGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>15q26.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="89318948" stop="89318949" display_start="89318948" display_stop="89318949" variantLength="1" positionVCF="89318948" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="89862179" stop="89862180" display_start="89862179" display_stop="89862180" variantLength="1" positionVCF="89862179" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
      </Location>
      <ProteinChange>S1086fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008218.2" sequenceAccession="NG_008218" sequenceVersion="2" change="g.20847dup">
            <Expression>NG_008218.2:g.20847dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126131.2" sequenceAccession="NM_001126131" sequenceVersion="2" change="c.3255dup">
            <Expression>NM_001126131.2:c.3255dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119603.1" sequenceAccession="NP_001119603" sequenceVersion="1" change="p.Ser1086fs">
            <Expression>NP_001119603.1:p.Ser1086fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_002693.3" sequenceAccession="NM_002693" sequenceVersion="3" change="c.3255dup" MANESelect="true">
            <Expression>NM_002693.3:c.3255dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_002684.1" sequenceAccession="NP_002684" sequenceVersion="1" change="p.Ser1086fs">
            <Expression>NP_002684.1:p.Ser1086fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.10" sequenceAccession="NC_000015" sequenceVersion="10" change="g.89318951dup" Assembly="GRCh38">
            <Expression>NC_000015.10:g.89318951dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.89862182dup" Assembly="GRCh37">
            <Expression>NC_000015.9:g.89862182dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011736.1" sequenceAccession="NG_011736" sequenceVersion="1" change="g.79989dup">
            <Expression>NG_011736.1:g.79989dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_765" sequenceAccession="LRG_765">
            <Expression>LRG_765:g.20847dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_500" sequenceAccession="LRG_500">
            <Expression>LRG_500:g.79989dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1596350386" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_002693.3(POLG):c.3255dup (p.Ser1086fs) AND Progressive sclerosing poliodystrophy" Accession="RCV000794071" Version="4">
        <ClassifiedConditionList TraitSetID="3716">
          <ClassifiedCondition DB="MedGen" ID="C0205710">Progressive sclerosing poliodystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-11-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002693.3(POLG):c.3255dup (p.Ser1086fs) AND multiple conditions" Accession="RCV001175294" Version="1">
        <ClassifiedConditionList TraitSetID="53903">
          <ClassifiedCondition DB="MedGen" ID="C3150914">Mitochondrial DNA depletion syndrome 4b</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="CN294859">Progressive external ophthalmoplegia with mitochondrial DNA deletions</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1834846">Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0205710">Progressive sclerosing poliodystrophy</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1843851">Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1843852">Spinocerebellar ataxia with epilepsy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no classification provided</ReviewStatus>
            <Description SubmissionCount="1">not provided</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-11-02" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2019-08-14" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">18546365</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3716" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="105" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Alpers-Huttenlocher Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA depletion syndrome 4A (Alpers type)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers diffuse degeneration of cerebral gray matter with hepatic cirrhosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers progressive infantile poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Poliodystrophia cerebri progressiva</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Progressive cerebral poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Diffuse cerebral degeneration in infancy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neuronal degeneration of childhood with liver disease, progressive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Infantile poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA Depletion Syndrome 4A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive sclerosing poliodystrophy</ElementValue>
                <XRef ID="Progressive+sclerosing+poliodystrophy/9168" DB="Genetic Alliance" />
                <XRef ID="20415001" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MTDPS4A</ElementValue>
                <XRef Type="MIM" ID="203700" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PNDC</ElementValue>
                <XRef Type="MIM" ID="203700" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</Attribute>
                <XRef ID="NBK26471" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5783" />
                <XRef ID="5783" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">POLG-Related Disorders</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301791</ID>
                <ID Source="BookShelf">NBK26471</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29517884</ID>
                <ID Source="BookShelf">NBK487393</ID>
              </Citation>
              <XRef ID="726" DB="Orphanet" />
              <XRef ID="C0205710" DB="MedGen" />
              <XRef ID="MONDO:0008758" DB="MONDO" />
              <XRef Type="MIM" ID="203700" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="53903" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="105" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Alpers-Huttenlocher Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA depletion syndrome 4A (Alpers type)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers diffuse degeneration of cerebral gray matter with hepatic cirrhosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers progressive infantile poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Poliodystrophia cerebri progressiva</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Progressive cerebral poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Diffuse cerebral degeneration in infancy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neuronal degeneration of childhood with liver disease, progressive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Infantile poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA Depletion Syndrome 4A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive sclerosing poliodystrophy</ElementValue>
                <XRef ID="Progressive+sclerosing+poliodystrophy/9168" DB="Genetic Alliance" />
                <XRef ID="20415001" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MTDPS4A</ElementValue>
                <XRef Type="MIM" ID="203700" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PNDC</ElementValue>
                <XRef Type="MIM" ID="203700" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</Attribute>
                <XRef ID="NBK26471" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5783" />
                <XRef ID="5783" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">POLG-Related Disorders</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301791</ID>
                <ID Source="BookShelf">NBK26471</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29517884</ID>
                <ID Source="BookShelf">NBK487393</ID>
              </Citation>
              <XRef ID="726" DB="Orphanet" />
              <XRef ID="C0205710" DB="MedGen" />
              <XRef ID="MONDO:0008758" DB="MONDO" />
              <XRef Type="MIM" ID="203700" DB="OMIM" />
            </Trait>
            <Trait ID="3384" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1</ElementValue>
                <XRef Type="MIM" ID="157640" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1</ElementValue>
                <XRef ID="MONDO:0024528" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PEOA1</ElementValue>
                <XRef Type="MIM" ID="157640" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</Attribute>
                <XRef ID="NBK26471" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="13174" />
                <XRef ID="13174" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301382</ID>
                <ID Source="BookShelf">NBK1203</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301791</ID>
                <ID Source="BookShelf">NBK26471</ID>
              </Citation>
              <Citation Type="general" Abbrev="MMS, 2017">
                <ID Source="PubMed">28749475</ID>
                <ID Source="pmc">7804217</ID>
              </Citation>
              <XRef ID="C1834846" DB="MedGen" />
              <XRef ID="MONDO:0024528" DB="MONDO" />
              <XRef Type="MIM" ID="157640" DB="OMIM" />
            </Trait>
            <Trait ID="4387" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Epilepsy, progressive myoclonic, type 5</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">SENSORY ATAXIC NEUROPATHY WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE</ElementValue>
                <XRef Type="MIM" ID="607459" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis</ElementValue>
                <XRef ID="Sensory+ataxic+neuropathy%2C+dysarthria%2C+and+ophthalmoparesis/6505" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011835" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">SANDO</ElementValue>
                <XRef Type="MIM" ID="607459" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EMP5</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</Attribute>
                <XRef ID="NBK26471" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9998" />
                <XRef ID="9998" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301791</ID>
                <ID Source="BookShelf">NBK26471</ID>
              </Citation>
              <XRef ID="70595" DB="Orphanet" />
              <XRef ID="C1843851" DB="MedGen" />
              <XRef ID="MONDO:0011835" DB="MONDO" />
              <XRef Type="MIM" ID="607459" DB="OMIM" />
            </Trait>
            <Trait ID="36464" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Progressive external ophthalmoplegia with mitochondrial DNA deletions</ElementValue>
                <XRef ID="MONDO:0000090" DB="MONDO" />
              </Name>
              <XRef ID="CN294859" DB="MedGen" />
              <XRef ID="MONDO:0000090" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS157640" DB="OMIM" />
            </Trait>
            <Trait ID="15731" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Mitochondrial DNA depletion syndrome 4b</ElementValue>
                <XRef ID="MONDO:0013350" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial Neurogastrointestinal Encephalopathy Disease, POLG-Related</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA depletion syndrome 4B, MNGIE type</ElementValue>
                <XRef ID="Mitochondrial+DNA+depletion+syndrome+4B%2C+MNGIE+type/8898" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MNGIE, POLG-RELATED</ElementValue>
                <XRef Type="MIM" ID="613662" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MTDPS4B</ElementValue>
                <XRef Type="MIM" ID="613662" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">POLG-Related Mitochondrial DNA Depletion Syndrome, MNGIE Form</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">POLG-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</Attribute>
                <XRef ID="NBK26471" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301791</ID>
                <ID Source="BookShelf">NBK26471</ID>
              </Citation>
              <XRef ID="298" DB="Orphanet" />
              <XRef ID="C3150914" DB="MedGen" />
              <XRef ID="MONDO:0013350" DB="MONDO" />
              <XRef Type="MIM" ID="613662" DB="OMIM" />
            </Trait>
            <Trait ID="9412" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Spinocerebellar ataxia with epilepsy</ElementValue>
                <XRef ID="MONDO:0016809" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">SCAE</ElementValue>
                <XRef ID="607459" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MEMSA</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17229" />
                <XRef ID="17229" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="254881" DB="Orphanet" />
              <XRef ID="C1843852" DB="MedGen" />
              <XRef ID="MONDO:0016809" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2647061" SubmissionDate="2020-04-22" DateLastUpdated="2020-06-22" DateCreated="2020-06-22">
        <ClinVarSubmissionID localKey="nvtaconnect_GM1_65166_932|MedGen:C3150914;C0205710;C1843851;C1843852;CN239267;C1834846" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001338916" DateUpdated="2020-06-22" DateCreated="2020-06-22" Type="SCV" Version="1" SubmitterName="GenomeConnect - GM1" OrgID="507208" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Comment>Variant interpreted as Pathogenic and reported on 12-19-2018 by Lab or GTR ID 500031. GenomeConnect-GM1 assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>paternal</Origin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>unknown</AffectedStatus>
              <Gender>male</Gender>
              <Indication Type="Indication">
                <Trait Type="Finding">
                  <Name>
                    <ElementValue Type="Preferred">Diagnostic</ElementValue>
                  </Name>
                </Trait>
              </Indication>
            </Sample>
            <Method>
              <TypePlatform>Exome Sequencing</TypePlatform>
              <MethodType>phenotyping only</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="TestingLaboratory" dateValue="2018-12-19" integerValue="500031">Invitae</Attribute>
                <Comment>Pathogenic</Comment>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <TraitSet DateLastEvaluated="2019-01-19" Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">Abnormality of eye movement</ElementValue>
                </Name>
                <XRef DB="HP" ID="HP:0000496" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">Abnormality of muscle physiology</ElementValue>
                </Name>
                <XRef DB="HP" ID="HP:0011804" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">Abnormality of coordination</ElementValue>
                </Name>
                <XRef DB="HP" ID="HP:0011443" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">Generalized hypotonia</ElementValue>
                </Name>
                <XRef DB="HP" ID="HP:0001290" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="POLG" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002693.2:c.3255dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Mitochondrial DNA depletion syndrome 4B, MNGIE type</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C3150914" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Progressive sclerosing poliodystrophy</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0205710" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C1843851" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Myoclonic epilepsy myopathy sensory ataxia</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C1843852" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Progressive External Ophthalmoplegia with Mitochondrial DNA Deletions</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="CN239267" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 1</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C1834846" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB7315086</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1827258" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="5640435|MedGen:C0205710" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000933455" DateUpdated="2024-02-20" DateCreated="2019-08-14" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-11-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">18546365</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 640935). This variant has not been reported in the literature in individuals affected with POLG-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ser1086Leufs*22) in the POLG gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in POLG are known to be pathogenic (PMID: 18546365).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="POLG" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000015.9:g.89862179_89862180insG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0205710" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2647061" TraitType="Disease" MappingType="Name" MappingValue="Mitochondrial DNA depletion syndrome 4B, MNGIE type" MappingRef="Preferred">
        <MedGen CUI="C3150914" Name="Mitochondrial DNA depletion syndrome 4b" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2647061" TraitType="Disease" MappingType="Name" MappingValue="Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 1" MappingRef="Preferred">
        <MedGen CUI="C1834846" Name="Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2647061" TraitType="Finding" MappingType="Name" MappingValue="Abnormality of eye movement" MappingRef="Preferred">
        <MedGen CUI="C0497202" Name="Abnormality of eye movement" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2647061" TraitType="Disease" MappingType="Name" MappingValue="Progressive sclerosing poliodystrophy" MappingRef="Preferred">
        <MedGen CUI="C0205710" Name="Progressive sclerosing poliodystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2647061" TraitType="Disease" MappingType="Name" MappingValue="Progressive External Ophthalmoplegia with Mitochondrial DNA Deletions" MappingRef="Preferred">
        <MedGen CUI="CN294859" Name="Progressive external ophthalmoplegia with mitochondrial DNA deletions" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2647061" TraitType="Finding" MappingType="Name" MappingValue="Abnormality of coordination" MappingRef="Preferred">
        <MedGen CUI="C4023353" Name="Abnormality of coordination" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1827258" TraitType="Disease" MappingType="XRef" MappingValue="C0205710" MappingRef="MedGen">
        <MedGen CUI="C0205710" Name="Progressive sclerosing poliodystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2647061" TraitType="Disease" MappingType="Name" MappingValue="Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome" MappingRef="Preferred">
        <MedGen CUI="C1843851" Name="Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2647061" TraitType="Finding" MappingType="Name" MappingValue="Abnormality of muscle physiology" MappingRef="Preferred">
        <MedGen CUI="C4023182" Name="Abnormal muscle physiology" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2647061" TraitType="Disease" MappingType="Name" MappingValue="Myoclonic epilepsy myopathy sensory ataxia" MappingRef="Preferred">
        <MedGen CUI="C1843852" Name="Spinocerebellar ataxia with epilepsy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2647061" TraitType="Finding" MappingType="Name" MappingValue="Generalized hypotonia" MappingRef="Preferred">
        <MedGen CUI="C1858120" Name="Generalized hypotonia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

